At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 59 enrolled
Drug / intervention
sorafenibdrug
Likely dose
sorafenib 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Cancer
In Brief
A Phase 2 clinical trial evaluating sorafenib for Metastatic Differentiated Thyroid Cancer and 3 related conditions. Completed, enrolled 59 participants across 1 site.
Detailed Summary
The goal of this study is to determine the activity of sorafenib in patients with advanced (metastatic or recurrent) thyroid cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Differentiated Thyroid Cancer, Metastatic Poorly Differentiated Thyroid Cancer, Metastatic Anaplastic Thyroid Cancer, Metastatic Medullary Thyroid Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2006
First PostedApr 2008
Primary CompletionDec 2010
Study CompletionMar 2011
TodayJul 2026
First PostedApr 7, 2008
Enrollment StartFeb 1, 2006
Primary CompletionDec 1, 2010
Study CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 18.2 years ago
Interventions
sorafenibdrug
400mg PO BID daily